Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Operating Leases (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Leases for 4 consecutive years, with $40.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 17.81% to $40.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, down 17.81% year-over-year, with the annual reading at $40.2 million for FY2025, 17.81% down from the prior year.
  • Operating Leases for Q4 2025 was $40.2 million at Century Therapeutics, down from $41.2 million in the prior quarter.
  • The five-year high for Operating Leases was $52.7 million in Q2 2024, with the low at $14.4 million in Q1 2022.
  • Average Operating Leases over 4 years is $41.7 million, with a median of $42.7 million recorded in 2024.
  • The sharpest move saw Operating Leases skyrocketed 185.29% in 2023, then fell 18.99% in 2025.
  • Over 4 years, Operating Leases stood at $38.7 million in 2022, then rose by 20.57% to $46.7 million in 2023, then rose by 4.93% to $49.0 million in 2024, then dropped by 17.81% to $40.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $40.2 million, $41.2 million, and $46.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.